Innoture, manufacturer of Radara, announces appointment of Ken Jones as new chief executive officer

Innoture Ltd, a multi-disciplinary medical technology company and manufacturers of aesthetic brand Radara, have announced the appointment of Ken Jones as their new CEO, effective immediately.

Jones, a highly accomplished business leader and former President and CEO of Astellas Pharma Europe Ltd brings over 30 years of global specialty pharmaceutical industry experience to the role. Prior to Astellas, Jones worked for Allergan for 17 years, including the role of Managing Director for Allergan UK and Ireland and was involved in the launches of several BOTOX® therapeutic indications, in addition to the development of the cosmetic indication.

“I’m excited about the opportunity to further develop the Radara brand and the broader micro-channelling patch technology platform and am committed to helping Innoture achieve its potential in aesthetics and beyond”, said Jones. “In a short time, Radara has achieved significant success thanks to the combination of innovative technology and the team’s passion and expertise. I believe there is a great opportunity for growth and development in the business and I look forward to driving Radara’s future success.”

Radara has been designed, developed and manufactured in the UK, with research directed by leading skincare advisors based at the state-of-the-art Institute of Life Science at Swansea University. Radara is the first and only patented micro-channelling skincare system designed to restore skin quality and diminish signs of ageing around the eyes, and was launched in the UK at the end of 2015.

As CEO, Jones will be responsible for driving growth and development of this exciting new brand within the medical aesthetic industry, as well as progressing various medical device and pharmaceutical applications for the unique micro-channelling patch technology.

Ben Fisher, managing director for Innoture said: “We are delighted to be welcoming Ken to the Innoture team. His wealth of business expertise as well as his understanding of ethical pharma and aesthetic markets will be invaluable as we look to take Radara forward and expand other opportunities in pharmaceutical areas.”